Genomic and proteomic biomarkers for Parkinson disease

Neurology

Volumn 72, Issue 7 SUPPL. 2, 2009, Pages

  Gasser, Thomas ^a  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; PROTEOME; TRANSCRIPTOME; PROTEIN;

DISEASE PREDISPOSITION; GENE; GENETIC RISK; GENOMICS; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SNCA GENE; GENETIC MARKER; GENETICS; METABOLISM; MUTATION;

ALPHA-SYNUCLEIN; BIOLOGICAL MARKERS; GENETIC MARKERS; HUMANS; MUTATION; PARKINSON DISEASE; PROTEINS; PROTEOME;

EID: 61949269129     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318198e054     Document Type: Article

References (25)

1. Poewe WH, Wenning GK. The natural history of Parkinson's disease. Neurology 1996;47:S146-S152.
2. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
3. Krüger R, Kuhn W, Müller T, et al. Ala39Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 1998;18:106-108.
4. Singleton AB, Farrer M, Johnson J, et al. α-synuclein locus triplication causes Parkinson's disease. Science 2003;302:841.
5. Fuchs J, Nilsson C, Kachergus J, et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007;68:916-922.
6. *. Brain 2005;128:3000-3011.
7. Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005;365:415-416.
8. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006;354:424-425.
9. Lesage S, Durr A, Tazir M, et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 2006;354:422-423.
10. Goldwurm S, Di Fonzo A, Simons EJ, et al. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet 2005;42:e65.
11. Maraganore DM, de Andrade M, Elbaz A, et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006;296:661-670.
12. Mueller JC, Fuchs J, Hofer A, et al. Multiple regions of alpha-synuclein are associated with Parkinson's disease. Ann Neurol 2005;57:535-541.
13. Mizuta I, Satake W, Nakabayashi Y, et al. Multiple candidate gene analysis identifies α-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet 2006;15:1151-1158.
14. Chiba-Falek O, Kowalak JA, Smulson ME, Nussbaum RL. Regulation of alpha-synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene. Am J Hum Genet 2005;76:478-492.
15. Fuchs J, Tichopad A, Golub Y, et al. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J 2008;22:1327-1334.
16. Fung HC, Chen CM, Hardy J, Singleton AB, Wu YR. A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. BMC Neurol 2006; 6:47.
17. Tan EK. Identification of a common genetic risk variant (LRRK2 Gly2385Arg) in Parkinson's disease. Ann Acad Med Singapore 2006;35:840-842.
18. Funayama M, Li Y, Tomiyama H, et al. Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. Neuroreport 2007;18:273-275.
19. Li QX, Mok SS, Laughton KM, et al. Plasma alpha-synuclein is decreased in subjects with Parkinson's disease. Exp Neurol 2007;204:583-588.
20. El-Agnaf OM, Salem SA, Paleologou KE, et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 2003;17:1945-1947.
21. Tokuda T, Salem SA, Allsop D, et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006;349:162-166.
22. El-Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006;20:419-425.
23. Scherzer CR, Eklund AC, Morse LJ, et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci USA 2007;104:955-960.
24. Exner N, Treske B, Paquet D, et al. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 2007;27:12413-12418.
25. Hoepken HH, Gispert S, Azizov M, et al. Parkinson patient fibroblasts show increased alpha-synuclein expression. Exp Neurol 2008;212:307-313.